Full Text Journal Articles about
Tardive Dyskinesia

Advertisement

Find full text journal articles






A preliminary exome sequence in three patients with tardive dystonia.

Nobuhisa Kanahara, Yusuke Nakata, Masaomi Iyo,

Tardive dystonia is one of the most serious adverse events that can be caused by antipsychotic treatment, but few studies have examined the etiology of tardive dystonia, and no genetic study using a next-generation sequencing technique has been performed to date. We conducted exome sequencing in three subjects with severe ... Read more >>

Psychiatr. Genet. (Psychiatric genetics)
[2020, 30(2):57-59]

Cited: 0 times

View full text PDF listing >>



A unifying theory for the pathoetiologic mechanism of tardive dyskinesia.

Ziad Ali, Autumn Roque, Rif S El-Mallakh,

INTRODUCTION:Chronic treatment with dopamine D2 receptor antagonists has been proposed to lead to dopamine receptor supersensitivity. Frequently, this is conceptualized as upregulation or changes in the structure or function of the post-synaptic D2 receptor. However, the measured 1.4-fold increase in D2 receptor density and the lack of actual receptor supersensitivity ... Read more >>

Med. Hypotheses (Medical hypotheses)
[2020, 140:109682]

Cited: 0 times

View full text PDF listing >>



Advertisement

Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.

Nicholas Keks, Judith Hope, Darren Schwartz, Harold McLennan, David Copolov, Graham Meadows,

Aripiprazole, brexpiprazole and cariprazine differ from all other second-generation antipsychotics due to partial agonism at the dopamine D2 and D3 receptors. In contrast to aripiprazole, brexpiprazole has lower intrinsic dopamine D2 activity and higher affinity for the serotonin 5-HT1A and 5-HT2A receptors, while cariprazine has the highest affinity for the ... Read more >>

CNS Drugs (CNS drugs)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.

Leslie Citrome, Stephen R Saklad,

The use of second-generation antipsychotics has not eliminated tardive dyskinesia (TD), and the prevalence of the disorder is higher than commonly realized. The involuntary movements of TD can decrease patients' quality of life, cause embarrassment, and lead to social withdrawal. Clinicians must evaluate patients taking DRBAs for TD risk factors ... Read more >>

J Clin Psychiatry (The Journal of clinical psychiatry)
[2020, 81(2):]

Cited: 0 times

View full text PDF listing >>



Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers.

Frank Schneider, Margaret Bradbury, Thomas A Baillie, David Stamler, Edward Hellriegel, Donna S Cox, Pippa S Loupe, Juha-Matti Savola, Laura Rabinovich-Guilatt,

Deutetrabenazine (Austedo, Teva Pharmaceuticals) is a deuterated form of tetrabenazine. It is the first deuterated drug to receive US regulatory approval and is approved for treatment of chorea in Huntington's disease and tardive dyskinesia. Two oral single dose studies comparing deutetrabenazine (25 mg) with tetrabenazine (25 mg) in healthy volunteers evaluated the ... Read more >>

Clin Transl Sci (Clinical and translational science)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.

Mei Huang, Wenqi He, Lakshmi Rajagopal, Andrea Kudwa, Dimitri E Grigoriadis, Herbert Y Meltzer,

Valbenazine, a vesicular monoamine transporter 2 (VMAT2, SLC18A2) inhibitor, is a newly approved treatment for tardive dyskinesia. VMAT2 is present in the membrane of secretory vesicles and transports dopamine (DA), norepinephrine (NE), serotonin (5-HT), histamine, glutamate (Glu), and GABA into vesicles for presynaptic release. We utilized microdialysis in awake, freely ... Read more >>

Pharmacol. Biochem. Behav. (Pharmacology, biochemistry, and behavior)
[2020, 190:172872]

Cited: 0 times

View full text PDF listing >>



Unilateral akathisia and choreoathetosis as an unusual presentation of a frontal lobe dermoid cyst.

Lindsey Bulleid, Christopher Wilcox, Tom Hughes, Paul A Leach,

Objective: To consider an unusual presentation of a frontal lobe dermoid cyst. Intracranial masses very rarely present with movement disorders. We describe a highly unusual presentation of an intracranial dermoid with unilateral choreoathetosis, akathisia and facial tics. Material: A 63-year-old man presented with left-sided akathisia and tardive dyskinesia of his ... Read more >>

Br J Neurosurg (British journal of neurosurgery)
[2020, :1-2]

Cited: 0 times

View full text PDF listing >>



Pyrosequencing analysis of IRS1 methylation levels in schizophrenia with tardive dyskinesia.

Yanli Li, Kesheng Wang, Ping Zhang, Junchao Huang, Ying Liu, Zhiren Wang, Yongke Lu, Shuping Tan, Fude Yang, Yunlong Tan,

Tardive dyskinesia (TD) is a serious side effect of certain antipsychotic medications that are used to treat schizophrenia (SCZ) and other mental illnesses. The methylation status of the insulin receptor substrate 1 (IRS1) gene is reportedly associated with SCZ; however, no study, to the best of the authors' knowledge, has ... Read more >>

Mol Med Rep (Molecular Medicine Reports)
[2020, 21(4):1702-1708]

Cited: 0 times

View full text PDF listing >>



Time for a New Slate in Tardive Dyskinesia Research.

Pierre J Blanchet, Daniel Lévesque,

Mov. Disord. (Movement disorders : official journal of the Movement Disorder Society)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Use of Valbenazine in a 54-Year-Old Female with Severe Tardive Dyskinesia.

Maria Ruiza Yee, Eduardo D Espiridion, John Gurski,

Tardive dyskinesia (TD) is a serious and often irreversible involuntary muscle movement that involves the face, lips, tongue, trunk, and extremities. TD is a risk in the use of antipsychotic medications, whether it is typical or first generation or atypical or second-generation antipsychotic. The risk is highest in patients receiving long-term antipsychotic ... Read more >>

Cureus (Cureus)
[2020, 12(1):e6801]

Cited: 0 times

View full text PDF listing >>



Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.

Leslie L Citrome,

Valbenazine and deutetrabenazine are FDA-approved as treatment for tardive dyskinesia (TD). Both medications are vesicular monoamine transporter type 2 (VMAT2) inhibitors, and both are effective for reducing TD symptoms. Clinicians need to be aware of the adverse effects of valbenazine and deutetrabenazine, as well as other key differences between the ... Read more >>

J Clin Psychiatry (The Journal of clinical psychiatry)
[2020, 81(2):]

Cited: 0 times

View full text PDF listing >>



Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia.

Joseph P McEvoy, Daniel E Kremens,

​​​​Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia Click to enlarge page​​. ... Read more >>

J Clin Psychiatry (The Journal of clinical psychiatry)
[2020, 81(1):]

Cited: 0 times

View full text PDF listing >>



A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia.

Stanley N Caroff, Leslie Citrome, Jonathan Meyer, Martha Sajatovic, Joseph F Goldberg, Rakesh Jain, Leslie Lundt, Jean-Pierre Lindenmayer, Joseph P McEvoy, Roger S McIntyre, Mauricio Tohen, Terence A Ketter,

OBJECTIVE:A nominal group process followed by a modified Delphi method was used to survey expert opinions on best practices for tardive dyskinesia (TD) screening, diagnosis, and treatment and to identify areas lacking in clinical evidence. PARTICIPANTS:A steering committee of 11 TD experts met in nominal group format to prioritize questions ... Read more >>

J Clin Psychiatry (The Journal of clinical psychiatry)
[2020, 81(2):]

Cited: 0 times

View full text PDF listing >>



Levosulpiride-Induced Neurological Adverse Effects: A Prospective Study from a Tertiary Care Center.

Jacob Joe,

Background:Levosulpiride (LS) is a prokinetic drug increasingly used for the gastric motility disorders. Despite its common use for the gastric motility disorder, the tendency to cause parkinsonism and acute dystonias are under-recognized as the major adverse effects. This study was aimed to evaluate the adverse effects of this drug in ... Read more >>

Ann Indian Acad Neurol (Annals of Indian Academy of Neurology)
[2020, 23(2):174-176]

Cited: 0 times

View full text PDF listing >>



Identifying Tardive Dyskinesia: Risk Factors, Functional Impact, and Diagnostic Tools.

Stephen R Saklad,

Tardive dyskinesia (TD) is an involuntary movement disorder induced by dopamine-receptor blocking agents (DRBAs), including antipsychotics. Because the introduction of second-generation antipsychotics has reduced but not eliminated the risk for TD as had been hoped, recognizing and treating TD are important skills for clinicians. Many patients rely on DRBAs for ... Read more >>

J Clin Psychiatry (The Journal of clinical psychiatry)
[2020, 81(1):]

Cited: 0 times

View full text PDF listing >>



Association of regulatory variants of dopamine β-hydroxylase with cognition and tardive dyskinesia in schizophrenia subjects.

Toyanji J Punchaichira, Anirban Mukhopadhyay, Prachi Kukshal, Triptish Bhatia, Smita N Deshpande, B K Thelma,

BACKGROUND:Dopamine-β-hydroxylase (DBH, EC 1.14.17.1), which converts dopamine to norepinephrine, is a candidate gene in neuropsychiatric diseases. AIM:To assess the effect of regulatory variants in DBH on schizophrenia and its endophenotypes -cognition and tardive dyskinesia. METHODS:We tested association of functional variants 19bp Ins/Del, rs1989787 and rs1611115 in DBH with i) schizophrenia ... Read more >>

J. Psychopharmacol. (Oxford) (Journal of psychopharmacology (Oxford, England))
[2020, 34(3):358-369]

Cited: 0 times

View full text PDF listing >>



Comment on Akbar et al., "Valbenazine-induced parkinsonism".

Chirag Shah,

This letter to the editor acknowledges the contribution of Akbar et al. to the field of tardive dyskinesia (TD) and provides important regulatory information about the potential for parkinson-like symptoms in patients with TD who are treated with valbenazine. ... Read more >>

Parkinsonism Relat. Disord. (Parkinsonism & related disorders)
[2020, 71:35]

Cited: 0 times

View full text PDF listing >>



Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.

Farah Khorassani, Kiranjit Luther, Om Talreja,

PURPOSE:The purpose of this review is to summarize the current evidence for valbenazine and deutetrabenazine use for the treatment of tardive dyskinesia (TD). SUMMARY:A literature search was conducted to gather relevant data regarding the use of valbenazine and deutetrabenazine for TD management. PubMed, MEDLINE, and ClinicalTrials.gov were searched using the ... Read more >>

Am J Health Syst Pharm (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists)
[2020, 77(3):167-174]

Cited: 0 times

View full text PDF listing >>



Abdominal Wall Dyskinesia: Case Report.

Leyla Cavdar, Solomon Ajasin, Scott Woolf, Robert Fekete,

The clinical presentation of repetitive choreiform involuntary movements of the anterior abdominal wall was first introduced as "belly dancer's dyskinesia." Etiologies of this rare condition include idiopathic causes, medication inducement, or post-abdominal surgery. We report a case of orobuccal stereotypic movements and abdominal wall dyskinesia secondary to prochlorperazine intake. The ... Read more >>

Case Rep Neurol (Case reports in neurology)
[2020, 12(1):69-72]

Cited: 0 times

View full text PDF listing >>



Methamphetamine use and antipsychotic-related extrapyramidal side-effects in patients with psychotic disorders.

Henk S Temmingh, Wim van den Brink, Fleur Howells, Goodman Sibeko, Dan J Stein,

Objective: Extrapyramidal side-effects (EPSE) are frequent in patients treated with antipsychotics and comorbid substance use disorders (SUDs). Methamphetamine has been shown to act as a dopaminergic neurotoxin. We aimed to determine whether EPSE occur more often in patients with psychotic disorders and co-occurring methamphetamine (MA) use disorders, and we examined ... Read more >>

J Dual Diagn (Journal of dual diagnosis)
[2020, :1-10]

Cited: 0 times

View full text PDF listing >>



The dentato-rubro-thalamic tract as the potential common deep brain stimulation target for tremor of various origin: an observational case series.

Volker Arnd Coenen, Bastian Sajonz, Thomas Prokop, Marco Reisert, Tobias Piroth, Horst Urbach, Carolin Jenkner, Peter Christoph Reinacher,

INTRODUCTION:Deep brain stimulation alleviates tremor of various origins. The dentato-rubro-thalamic tract (DRT) has been suspected as a common tremor-reducing structure. Statistical evidence has not been obtained. We here report the results of an uncontrolled case series of patients with refractory tremor who underwent deep brain stimulation under tractographic assistance. METHODS:A ... Read more >>

Acta Neurochir (Wien) (Acta neurochirurgica)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Treatment Strategies for Tardive Dyskinesia.

Daniel E Kremens,

Tardive dyskinesia (TD), a condition of potentially irreversible abnormal involuntary movements that is associated with dopamine receptor blocking agents (DRBAs), produces significant impairment of functioning and quality of life for patients. Contrary to expectations, TD has not vanished despite the introduction of SGAs. Instead, changing prescription practices and increased off-label ... Read more >>

J Clin Psychiatry (The Journal of clinical psychiatry)
[2019, 81(1):]

Cited: 0 times

View full text PDF listing >>



FDA-Approved Medications to Treat Tardive Dyskinesia.

Joseph P McEvoy,

Tardive dyskinesia (TD), a condition characterized by involuntary movements, is found in patients taking antipsychotics or other agents that block dopamine receptors. Symptoms of TD are associated with reduced quality of life, psychosocial problems, and medication nonadherence. Few agents tested in the treatment of TD had sufficient data to support ... Read more >>

J Clin Psychiatry (The Journal of clinical psychiatry)
[2019, 81(1):]

Cited: 0 times

View full text PDF listing >>



Earlier Diagnosis of Tardive Dyskinesia.

Daniel E Kremens,

Because the symptoms of tardive dyskinesia (TD) have an insidious onset and fluctuating nature, and the risk of TD associated with second-generation antipsychotic (SGA) treatment has been underestimated, it has been challenging for clinicians to make an early and accurate TD diagnosis. More patients are at risk of developing this ... Read more >>

J Clin Psychiatry (The Journal of clinical psychiatry)
[2019, 81(1):]

Cited: 0 times

View full text PDF listing >>



Use of Botulinum Toxin in Orofacial Clinical Practice.

Maria-Angeles Serrera-Figallo, Gonzalo Ruiz-de-León-Hernández, Daniel Torres-Lagares, Alejandra Castro-Araya, Omar Torres-Ferrerosa, Esther Hernández-Pacheco, Jose-Luis Gutierrez-Perez,

INTRODUCTION:Botulinum neurotoxin (BoNT) is a potent biological toxin and powerful therapeutic tool for a growing number of clinical orofacial applications. BoNT relaxes striated muscle by inhibiting acetylcholine's release from presynaptic nerve terminals, blocking the neuromuscular junction. It also has an antinociceptive effect on sensory nerve endings, where BoNT and acetylcholine ... Read more >>

Toxins (Basel) (Toxins)
[2020, 12(2):]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
2.1718 s